ClinicalTrials.gg
Status unknownNCT05843422Updated May 6, 2023

A First-in-Human Study of QY211 Gel in Adult Subjects

A Phase 1 interventional study of 0.1% QY211 Gel or placebo and 0.3% QY211 Gel or placebo in Atopic Dermatitis, sponsored by E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-06.

Sponsored by E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Mar 2023), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 207 studies in Dermatitis, Atopic with a site in China — 65 open to participants now, 83 under way, 29 of them phase 3. Dermatitis, Atopic · China.

Planned enrollment
154th of 191
56 · median 163
Started
2023
with 38 others
Phase 1
39 of 207
15 open now
Registered
69th of 207
by date

Among the 207 studies in Dermatitis, Atopic with a site in China, this one is the 154th largest by planned enrollment of the 191 interventional ones that give a count, is one of 39 that started in 2023, is one of 39 in phase 1, and was the 69th registered.

Dermatitis, Atopic

1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

65 of the 207 studies in Dermatitis, Atopic with a site in China are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 207 studies in Dermatitis, Atopic with a site in China, or all of them as a file.
02

Study summary

This is a phase Ia/Ib,Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of Single and Multiple Topical Doses of QY211 Gel in Healthy Chinese Subjects and Patients with Mild to Moderate Atopic Dermatitis

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Part 1

  1. Male or female subjects (male or female) aged 18-45 years (inclusive);
  2. Body weight ≥ 50.0 kg for males and ≥ 45.0 kg for females; (BMI) within the range of 18.0 to 27.0 kg/m2 (including the cut-off value);
  3. the investigator determined vital signs, physical examination, clinical laboratory test values (blood routine, urine routine, blood biochemistry, coagulation function, pregnancy test (female), hepatitis, , syphilis), routine 12-lead results in line with healthy subjects
  4. the subject fully understood the purpose, nature, methods and possible adverse reactions of the trial, volunteered to participate, and signed before the start of any study procedures;
  5. the subject was able to communicate well with the investigator, and understand and comply with the requirements of this study.

Part 2

  1. Male and female patients aged 18-65 years (including the boundary value);
  2. Meet Hanifin-Rajka diagnostic criteria at screening and have a history of AD for at least 6 months ;
  3. IGA score of 2 (mild) or 3 (moderate) at screening and baseline;
  4. The total area of atopic dermatitis lesions is 5% -20% BSA
  5. Patients fully understand the purpose, nature, methods and possible adverse reactions of the trial, voluntarily participate, and sign an informed consent form before the start of any study procedures;
  6. Patients can communicate well with the investigator and comply with the study and follow-up procedures;

Exclusion criteria

Exclusion Criteria:

Part 1

  1. Allergic constitution, such as allergic to two or more drugs and food; or known to be allergic to the composition of this drug (QY201 and : carbomer (homopolymer type B 974P NF), edetate disodium, sodium hydroxide, propylene glycol and purified water);
  2. Patients who have received surgery within 3 months before screening, or plan to undergo surgery during the study period, or have received surgery that will affect drug absorption, distribution, metabolism and excretion;
  3. Previous or current cardiovascular, liver, kidney, respiratory, blood and lymphatic, endocrine, immune, mental, neurological, gastrointestinal system, metabolism and bone diseases, and the investigators believe that the subjects have clinical significance, not suitable for the trial;
  4. Patients who can not tolerate venipuncture, have a history of fainting needle, halo blood;
  5. History or presence of skin diseases that, in the opinion of the investigator, contraindicate the study or affect the assessment of the site of administration, including psoriasis, eczema, acne, atopic dermatitis, dysplastic mole, other skin lesions, history of skin cancer, or skin diseases that affect the safety evaluation of the test drug;
  6. Vaccination with live (attenuated) vaccines within 2 months prior to screening;
  7. Smoking or drinking within 3 months before screening (smoking: > 10 cigarettes/day; drinking: > 15 g pure alcohol/day, equivalent to 450 mL beer, 150 mL wine or 50 mL low-grade liquor), or alcohol and drug abuse (morphine/methylamphetamine/ketamine/methylenedioxyamphetamine/tetrahydrocannabinolic acid/cocaine) test positive;
  8. Participated in other drug or device clinical trials within 3 months before screening;
  9. Non-physiological blood loss ≥ 400 mL (including trauma, blood collection, blood donation) within 3 months before screening, or plan to donate blood during the study or within 1 month after the end of the study;
  10. Pregnant women, lactating women, or subjects who have plans to donate sperm or eggs, or (including male and female subjects) refuse to voluntarily take effective measures from the screening period to 6 months after the end of the last dose;
  11. Use of any other drugs, including oral or topical drugs such as prescription drugs, over-the-counter drugs, and herbal medicines, except vitamins and/or paracetamol, within 2 weeks before screening;
  12. Drinking excessive tea, coffee and/or caffeine-rich beverages (more than 8 cups, 1 cup = 250 mL) every day within 3 months before screening;
  13. Subjects have skin conditions in the target application area (back, lateral arm area) that affect the tolerability assessment of the study, such as tattoos;
  14. Subjects who are judged unsuitable for participation by other investigators;

Part 2

  1. Patients with or suspected active tuberculosis, latent untreated tuberculosis, incompletely cured tuberculosis or Mycobacterium tuberculosis infection (except for treatment records that prove that patients have been adequately treated, according to the medical judgment of the investigator and/or infectious disease experts, can enter this study) as judged by the investigator and/or infectious disease specialist (combined with medical history, symptoms, signs, laboratory tests, T-spot test, imaging examination);
  2. surface antigen (HBsAg) positive or virus antibody (HCV-Ab) positive during screening; or antibody or Treponema pallidum antibody positive;
  3. Patients with any clinical symptoms of bacterial, viral, parasitic or fungal infection requiring treatment during the screening period;
  4. Previous disseminated herpes zoster (single attack), or disseminated herpes simplex (single attack), or recurrent (≥ 2 attacks) local herpes zoster;
  5. Patients with a history of mental illness or genetic history of mental illness or epilepsy, the use of antipsychotic drugs, sedative drugs;
  6. In addition to a history of atopic dermatitis, previous history of other connective tissue diseases, or severe cardiovascular, liver, kidney, digestive tract, nerve, skin and other diseases, or patients with malignant tumors (except completely removed cervical carcinoma in situ or non- cutaneous squamous cell carcinoma or basal cell carcinoma), systemic sex hormone therapy or other interventions may be required, and participation in this study may be at risk as judged by the investigator;
  7. Patients with non-immune factors (such as hyperlipidemia, diabetes, thyroid disease, severe heart abnormalities, etc.);
  8. Patients who have previously suffered from lymphatic diseases, or have signs or symptoms of lymphoproliferative diseases, including but not limited to lymph nodes or splenomegaly;
  9. In addition to atopic dermatitis, suffering from other skin diseases that affect the evaluation of the test results, or the presence of large tattoos, birthmarks, skin scars and other conditions in the skin lesions;
  10. Known immunodeficiency disease or first-degree relatives with hereditary immunodeficiency disease;
  11. Patients with cerebral hemorrhage or cerebral infarction within 1 year;
  12. Patients with previous thromboembolism (including deep venous thrombosis, pulmonary embolism, arterial thrombosis, etc.) or other high-risk groups prone to thromboembolism;
  13. Previous or planned organ transplantation (such as liver and kidney transplantation);
  14. Clinical or laboratory tests judged by the investigator as abnormal with clinical significance;
  15. History of alcoholism or drug abuse within 6 months before screening;
  16. Participated in any drug 4 weeks (or 5 half-lives, whichever is longer) before screening or participated in any medical device clinical trial within 3 months;
  17. Non-physiological blood loss ≥ 400 mL (including trauma, blood sampling, blood donation) within 3 months before screening, or plan to donate blood during the study or within 1 month after the end of the study;
  18. Patients with the following cardiac abnormalities:

    1. Acute myocardial infarction, unstable angina pectoris, coronary artery bypass grafting or coronary stent implantation within 3 months prior to screening;
    2. Severe arrhythmia (e.g., second-degree type 2 or third-degree atrioventricular block, long syndrome or QTcF abnormalities: male > 470 ms female > 480 ms, atrial fibrillation, frequent premature beats);
    3. Decompensated cardiac insufficiency ( class III or IV);
    4. Other cardiac diseases requiring treatment and assessed by the investigator as inappropriate for participation in this study;
  19. Systemic or local use of JAK inhibitors (eg, Ruxolitinib, Tofacitinib, Baricitinib, Filgotinib, Lestaurtinib, Pacritinib, Delgocitinib, Upadacitinib, Abrocitinib, etc) within 3 months prior to screening;
  20. Major surgical procedures or serious trauma within 8 weeks prior to screening or anticipation of major surgical procedures during the trial (defined as major surgical procedures referring to Grade 3 and 4 procedures as specified in the Measures for the Management of Clinical Applications of Medical Technology implemented on November 1, 2018), and all surgical or major trauma-related AEs had not recovered (recovered to CTCAEv5.0 ≤ Grade 1 or baseline) before screening.
  21. Received biological therapy for atopic dermatitis (including but not limited to dupilumab) within 8 weeks (or 5 elimination half-lives, whichever is longer) before randomization;
  22. Received live (attenuated) vaccine within 4 weeks before randomization, or planned to receive live (attenuated) vaccine during treatment and within 4 weeks after the last use of investigational product;
  23. Patients who have used long-acting anticoagulants (such as warfarin, dabigatran, etc.) or need to continue anticoagulant therapy (except aspirin ≤ 100 mg/day) within 4 weeks before randomization;
  24. Receiving systemic therapy (including , cyclosporine, mycophenolate mofetil, interferon γ, azathioprine, methotrexate, tripterygium wilfordii tablets and other Chinese herbal medicines) known or likely to affect atopic dermatitis within 4 weeks (or 5 half-lives, whichever is longer) before randomization, phototherapy (such as UVB, PUVA, etc.) or receiving antihistamines within 2 weeks before randomization;
  25. Patients who have received topical drugs known or likely to affect atopic dermatitis within 2 weeks before randomization, including but not limited to topical glucocorticoids (TCS), calcineurin inhibitors (TCI), topical phosphodiesterase 4 (PDE 4) inhibitors;
  26. Use of topical antibiotics, antibacterial soap, sodium hypochlorite in the target application area within 7 days before randomization, or use of emollients not provided by the sponsor or designated by the investigator within 12 hours before baseline;
  27. Allergic constitution or suspected allergy to the active ingredients or excipients of the investigational drug;
  28. Pregnant women, lactating women, or patients (including male and female patients) refuse to voluntarily take effective contraceptive measures during the screening period until 6 months after the end of the last dose (see Appendix 2 for details);
  29. Do not avoid prolonged exposure to natural or artificial ultraviolet (UV) radiation, or plan to perform such exposure during the study, and the investigator believes that it may affect atopic dermatitis;
  30. Any patient considered unsuitable for participation in this clinical study by the investigator.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    part 1-0.8% QY211 Gel or placebo(10%BSA)

    6 subjects use 0.8% QY211 Gel,2 subject uses 0.8% QY211 placebo ,11days(Day1 QD,Day4-Day10 BID,Day11 QD ).

    Drug: 0.8% QY211 Gel or placebo

  • Experimental
    part 1-1.5% QY211 Gel or placebo(10%BSA)

    6 subjects use 0.8% QY211 Gel,2 subject uses 0.8% QY211 placebo ,11days(Day1 QD,Day4-Day10 BID,Day11 QD ).

    Drug: 1.5% QY211 Gel or placebo

  • Experimental
    part 1-1.5% QY211 Gel or placebo(20%BSA)

    6 subjects use 0.8% QY211 Gel,2 subject uses 0.8% QY211 placebo ,11days(Day1 QD,Day4-D10 BID,Day11 QD ).

    Drug: 1.5% QY211 Gel or placebo

  • Experimental
    part 2-0.1% QY211 Gel or placebo

    6 subjects use 0.1% QY211 Gel,2 subject uses 0.1% QY211 placebo ,29days(Day1-Day28 BID,Day29 QD).

    Drug: 0.1% QY211 Gel or placebo

  • Experimental
    part 2-0.3% QY211 Gel or placebo

    6 subjects use 0.3% QY211 Gel,2 subject uses 0.3% QY211 placebo ,29days(Day1-Day28 BID,Day29 QD).

    Drug: 0.3% QY211 Gel or placebo

  • Experimental
    part 2-0.8% QY211 Gel or placebo

    6 subjects use 0.3% QY211 Gel,2 subject uses 0.3% QY211 placebo ,29days(Day1-Day28 BID,Day29 QD).

    Drug: 0.8% QY211 Gel or placebo

  • Experimental
    part 2-1.5% QY211 Gel or placebo

    6 subjects use 0.3% QY211 Gel,2 subject uses 0.3% QY211 placebo ,29days(Day1-Day28 BID,Day29 QD).

    Drug: 1.5% QY211 Gel or placebo

Interventions

  • Drug0.1% QY211 Gel or placebo

    QY211 Gel or placebo topical applied to skin

  • Drug0.3% QY211 Gel or placebo

    QY211 Gel or placebo topical applied to skin

  • Drug0.8% QY211 Gel or placebo

    QY211 Gel or placebo topical applied to skin

  • Drug1.5% QY211 Gel or placebo

    QY211 Gel or placebo topical applied to skin

06

What researchers measure

Primary outcomes

  1. Part1:Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.

    Time frame: Day 1 to Day 13

  2. Part1:Number of Participants With Clinical Laboratory Abnormalities

    A treatment-emergent laboratory abnormality was defined as an increase of at least 1 abnormality grade from baseline and occurring after the first dose of study drug

    Time frame: Day 3 to Day 13

  3. Part1:Number of Participants With Clinically Significant Changes Form Baseline in Physical Examination

    Time frame: Day 3 to Day 13

  4. Part1:Number of Participants With Clinically Significant Treatment-emergent Electrocardiogram (ECG) Findings

    ECG data will be monitored

    Time frame: Day 3 to Day 13

  5. Part 1:Number of Participants With Clinically Significant Changes Form Baseline in Vital Signs

    Time frame: Day 1 to Day 13

  6. Part 1:Severity of local skin irritation

    Skin irritation response assessment recording method: ① subjective symptoms: including itching, pain, or burning sensation, evaluated according to the 4-level method: 0=none; 1=mild, without affecting daily life and sleep; 2=Moderate, affecting daily life but not sleep; 3=Severe, affecting sleep.The signs of skin lesions include erythema, papules, edema, blisters, bullae, exudates, pustules, erosion, exudates, ulcers, hypertrophy, desquamation, etc., which can be evaluated according to the 4-level method: 0=none; 1=Mild, with only blurred erythema, no edema (skin lesions not palpable), and papules; 2=Moderate, clear erythema with edema (skin lesions can be touched) and papules; "3=Severe, with blisters, bullae, exudates or pustules, erosion, exudates or ulcers.

    Time frame: Day 1 to Day 13

  7. Part 2:Number of Participants With Adverse Events (AEs) and Serious Adverse Events

    An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.

    Time frame: Day 1 to Day 31

  8. Part2:Number of Participants With Clinical Laboratory Abnormalities

    A treatment-emergent laboratory abnormality was defined as an increase of at least 1 abnormality grade from baseline and occurring after the first dose of study drug

    Time frame: Day 8 to Day 29

  9. Part2:Number of Participants With Clinically Significant Changes Form Baseline in Physical Examination

    Time frame: Day 8 to Day 29

  10. Part2:Number of Participants With Clinically Significant Treatment-emergent Electrocardiogram (ECG) Findings

    ECG data will be monitored

    Time frame: Day 8 to Day 29.

  11. Part 2:Number of Participants With Clinically Significant Changes Form Baseline in Vital Signs

    Time frame: Day 8 to Day 30

Secondary outcomes

  1. Rate of change from baseline in Eczema Area and Severity Index (EASI) in patients(part 2 only)

    EASI quantifies severity of AD based on severity of lesion clinical signs and percentage (%) of body surface area (BSA) affected. Severity of clinical signs of AD lesions (erythema, induration /papulation, excoriation and lichenification) were scored separately for each of 4 body regions (head and neck, upper limbs, trunk and lower limbs ) on a 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based on % BSA with AD in body region: 0 (0%), 1 (0 to 9%), 2 (10 to 29%), 3 (30 to 49%), 4 (50 to 69%), 5 (70 to 89%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, with higher scores indicating greater severity of AD.

    Time frame: Up to 4 weeks

  2. Proportion of patients with at least a 2-point improvement in IGA score from baseline(part 2 only)

    The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participants' psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).Proportion of patients with Investigator's Global Assessment (IGA) score of 0 or 1 and an improvement of at least 2 points in IGA score from baseline at 1, 2, 3 and 4 weeks after treatment.

    Time frame: Up to 4 weeks

  3. Percentage of Participants Achieving >=50%/75%/90% Improvement From Baseline in Eczema Area and Severity Index (EASI-50/EASI-75/EASI-90) Response(part2 only)

    EASI quantifies severity of AD based on severity of lesion clinical signs and percentage (%) of body surface area (BSA) affected. Severity of clinical signs of AD lesions (erythema, induration/papulation, excoriation and lichenification) were scored separately for each of 4 body regions (head and neck, upper limbs, trunk and lower limbs ) on a 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based on % BSA with AD in body region: 0 (0%), 1 (0 to 9%), 2 (10 to 29%), 3 (30 to 49%), 4 (50 to 69%), 5 (70 to 89%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, with higher scores indicating greater severity of AD.

    Time frame: Up to 4 weeks

  4. Change from baseline in Peak daily Pruritus NRS score (PP-NRS) (part 2 only)

    Change from baseline in Peak daily Pruritus NRS score (PP-NRS) during treatment.Using a 0 to 10 point scale, 0 represents "" no itching "" and 10 represents "" worst itch imaginable "",Rating the degree of itchiness experienced in the past 24 hours.

    Time frame: Up to 29 days

  5. Rate of change from baseline in SCORAD score (part 2 only)

    SCORAD (Severity Scoring of Atopic Dermatitis) Change from Baseline to Week 8 of atopic dermatitis lesion as measured by the Scoring of Atopic Dermatitis (SCORAD). SCORAD is a composite severity index comprising a) the amount/extent of body area affected; b) 2 subjective symptom of pruritus (0-10 points) and sleep disturbance measured (0-10 points); and c) 6 disease intensity assessments \[Dryness/Scaling, Erythema, Excoriation, Induration/Papulation, Lichenification and Oozing/ Weeping/Crusting, each grades from 0 (None) to 3 (Severe). A SCORAD score ranges from 0 (No AD present) to 103.

    Time frame: Up to 4 weeks

  6. Change from baseline in total score of Dermal Quality of Life Index Questionnaire (DLQI) (part 2 only)

    The DLQI is a dermatology-specific quality of life (QOL) instrument designed to assess impact of disease on a participants QOL. It is a 10-item questionnaire that, in addition to evaluating overall, QOL can be used to assess 6 different aspects: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships and treatment. Questions scored on a 4-point Likert scale: 0 (not relevant), 1 (a little), 2 (a lot), and 3 (very much). Scores of individual items (0-3) were added to yield a total score (0-30); higher score = greater impairment of participants QOL.

    Time frame: Up to 4 weeks

  7. Rate of change from baseline in atopic dermatitis in BSA(part 2 only)

    Rate of change from baseline in atopic dermatitis in BSA at Weeks 1, 2, 3, and 4 postdose.

    Time frame: Up to 4 weeks

  8. Tmax of QY211-Single and Multiple Dose Drugs

    Time of maximum concentration(single Dose and Steady state PK)

    Time frame: Up to 29 days

  9. Cmax of QY211-Single and Multiple Dose Drugs

    Maximum observed plasma concentration(single Dose and Steady state PK)

    Time frame: Up to 29 days

  10. t1/2 of QY211-Single and Multiple Dose Drugs

    The time it takes for the blood concentration of the drug to drop by half from the highest value in the body(single Dose and Steady state PK)

    Time frame: Up to 29 days

  11. AUC QY211-Single and Multiple Dose Drugs

    Area under the plasma concentration-time curve from time zero to the last quantifiable concentration(single Dose and Steady state PK)

    Time frame: Up to 29 days

07

Study locations

1 of 1 sites recruiting
  • Huashan Hospital Affiliated to Fudan University
    Shanghai, Shanghai, China
    Recruiting
    • CuiYun Wu · Contactwucuiyun@fudan.edu.cn · 021-52888045
    • Jing Zhang, Ph.D, M.D · Principal investigator
    • JinHua Xu, Ph.D, M.D · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Oct 2024, 19 months after the start.

Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's planned 19 months is above that.

Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2023
First posted
May 6, 2023
StartActual
Mar 1, 2023
Primary completionEst.
Oct 23, 2024
CompletionEst.
Oct 23, 2024
Last update
May 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05843422
Lead sponsor
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
Responsible party
Sponsor
First posted
May 6, 2023
Start date
Mar 1, 2023
Primary completion
Oct 23, 2024 (estimated)
Completion
Oct 23, 2024 (estimated)
Last update
May 6, 2023

Study contacts

Jing Zhang, Ph.D, M.D
Contact
zhangj_fudan@163.com
021-52888045

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion